Amylyx Pharmaceuticals Inc (AMLX)vsAstraZeneca PLC (AZN)
AMLX
Amylyx Pharmaceuticals Inc
$14.73
-3.09%
HEALTHCARE · Cap: $1.69B
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates -9088671% more annual revenue ($60.44B vs $-665,000). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AMLX
Avoid31
out of 100
Grade: F
AZN
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMLX.
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
AMLX has a balanced fundamental profile.
Bull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Market Cap, Profit Margin.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Key Dynamics to Monitor
AMLX profiles as a value stock while AZN is a mature play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.22 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 31/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating innovative therapies for neurodegenerative conditions, with a strong emphasis on amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, showcases a novel neuroprotective mechanism that aims to significantly improve patient outcomes, representing a promising advancement in ALS treatment. With a solid clinical development pipeline and a deep expertise in the nuances of neurological disorders, Amylyx is strategically positioned to address urgent unmet medical needs in ALS and potentially other related diseases, making it a compelling prospect for institutional investors.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?